Clinical Trials Sponsored by Shanghai Junshi Bioscience Co., Ltd.

Total 1177 results

Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Nanfang Hospital of Southern Medical University
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial (NICE)

Gastric Cancer | Stomach Neoplasm

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC (Escape)

Esophageal Squamous Cell Carcinoma Abdominal Stage 0

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Esophageal Small Cell Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects

Idiopathic Pulmonary Fibrosis

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Advanced Lung Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW031 in PMO Subjects

Osteoporosis, Postmenopausal

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Bone Metastases

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults (MW032)

Bone Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects

Pulmonary Fibrosis | Tumor

Australia
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

6MW3511 in Patients With Advanced Solid Tumor

Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

Lymphoma
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 in Patients With Renal Cancer

Advanced Clear Cell Renal Cell Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Solid Tumors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19

Covid19

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection

Asthma | Atopic Dermatitis | COPD

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults (MW031)

Osteoporosis, Postmenopausal

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study of 7MW3711 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections

Skin Infection

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Wet Age-related Macular Degeneration

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm

Advanced Malignant Neoplasm

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Active, not recruiting

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

Healthy

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Active, not recruiting

An Evaluation of 9MW1911 Injection in Healthy Subjects

Asthma | Atopic Dermatitis | COPD

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Breast Cancer Female

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Eli Lilly and Company
Shanghai Junshi Bioscience Co., Ltd.; AbCellera Biologics Inc.

Completed

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)

COVID-19

United States
Shanghai Runshi Pharmaceutical Technology Co., Ltd

Not yet recruiting

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

Advanced Solid Tumor

China
Guangdong Provincial Hospital of Traditional Chinese...
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis

Gastric Cancer | Chemotherapy

China
Shanghai Runshi Pharmaceutical Technology Co., Ltd

Not yet recruiting

Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants

Healthy Participants
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient

COVID-19 Patient

China
Shanghai Vinnerna Biosciences Co., Ltd.

Active, not recruiting

Effect of Pharmacokinetics in Healthy Chinese Subjects

The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects

China
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-World Study of JT001 for COVID-19

COVID-19

China
Second Affiliated Hospital, School of Medicine,...
Shanghai Junshi Bioscience Co., Ltd.; Qilu Pharmaceutical Co., Ltd.

Unknown

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer (BEVTOR)

MSS | pMMR | Refractory Metastatic Colorectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC (InTRist)

Local Advanced Non-small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis

Metastatic Colorectal Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.
Huashan Hospital

Completed

A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection

Staphylococcus Aureus Infection

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function

Subjects With Liver Function Injury | Normal Liver Function Subject

China

Clinical Trials Sponsored by Shanghai Junshi Bioscience Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations